{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:01:17Z","timestamp":1792526477762,"version":"4.5.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017170","name":"Thailand Science Research and Innovation","doi-asserted-by":"crossref","award":["FFB670043\/0401"],"award-info":[{"award-number":["FFB670043\/0401"]}],"id":[{"id":"10.13039\/501100017170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Health Syst."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Health technology faces rising costs, system complexities, and gaps between development and coverage policies, limiting translation into practice. Traditional health technology assessment (HTA) evaluates technologies at late stages, providing little support if a technology fails to secure reimbursement. Early HTA addresses this by assessing technologies during research and development stages, helping innovators prioritise disease areas, define target product profiles, and establish value propositions. Early HTA could reduce development risks and uncertainties and inform development choices that could improve cost-effectiveness and enhance long-term viability, adaptability, and adoptability in the healthcare system.<\/jats:p>","DOI":"10.1038\/s44401-026-00102-2","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:05:01Z","timestamp":1781852701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Introduction of early health technology assessment for innovators, clinicians, and funders"],"prefix":"10.1038","volume":"3","author":[{"given":"Teerawat","family":"Wiwatpanit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yot","family":"Teerawattananon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"102_CR1","unstructured":"National Research Council (US) and Institute of Medicine (US) Board on Science, Technology, and Economic Policy; Aspden P, editor. Medical Innovation in the Changing Healthcare Marketplace: Conference Summary. Washington (DC): National Academies Press (US); 2002. 5, Barriers to Medical Innovation. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK220587\/."},{"key":"102_CR2","first-page":"205","volume":"7","author":"J Bergsland","year":"2014","unstructured":"Bergsland, J., Elle, O. J. & Fosse, E. Barriers to medical device innovation. Med Devices (Auckl.) 7, 205\u2013209 (2014).","journal-title":"Med Devices (Auckl.)"},{"key":"102_CR3","unstructured":"What is the Medical Device Development Process? (Includes Stages) - TWI. https:\/\/www.twi-global.com\/technical-knowledge\/faqs\/what-is-the-medical-device-development-process."},{"key":"102_CR4","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/14737167.2022.2086122","volume":"22","author":"B Sapkota","year":"2022","unstructured":"Sapkota, B. et al. Gap analysis in manufacturing, innovation and marketing of medical devices in the Asia-Pacific region. Expert Rev. Pharmacoecon. Outcomes Res. 22, 1043\u20131050 (2022).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"102_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.2471\/BLT.15.155721","volume":"94","author":"K Chalkidou","year":"2016","unstructured":"Chalkidou, K. et al. Priority-setting for achieving universal health coverage. Bull. World Health Organ 94, 462\u2013467 (2016).","journal-title":"Bull. World Health Organ"},{"key":"102_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12992-023-00947-4","volume":"19","author":"PM Sahoo","year":"2023","unstructured":"Sahoo, P. M., Rout, H. S. & Jakovljevic, M. Future health expenditure in the BRICS countries: a forecasting analysis for 2035. Glob. Health 19, 49 (2023).","journal-title":"Glob. Health"},{"key":"102_CR7","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2147\/RMHP.S406491","volume":"16","author":"PM Sahoo","year":"2023","unstructured":"Sahoo, P. M., Rout, H. S. & Jakovljevic, M. Contemporary Universal Health Coverage in India\u2014The Case of Federal State of Odisha (Orissa). Risk Manag. Healthc. Policy 16, 1131\u20131143 (2023).","journal-title":"Risk Manag. Healthc. Policy"},{"key":"102_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/14737167.2023.2219447","volume":"23","author":"J Sukmanee","year":"2023","unstructured":"Sukmanee, J. et al. The impact of universal health coverage and COVID-19 pandemic on out-of-pocket expenses in Thailand: an analysis of household survey from 1994 to 2021. Expert Rev. Pharmacoecon. Outcomes Res. 23, 823\u2013830 (2023).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"102_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.7326\/M20-1234","volume":"174","author":"WV Padula","year":"2021","unstructured":"Padula, W. V. & Sculpher, M. J. Ideas about resourcing health care in the United States: can economic evaluation achieve meaningful use?. Ann. Intern. Med. 174, 80\u201385 (2021).","journal-title":"Ann. Intern. Med."},{"key":"102_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/13696998.2021.2007691","volume":"24","author":"M Jakovljevic","year":"2021","unstructured":"Jakovljevic, M. et al. The Global South political economy of health financing and spending landscape\u2014history and presence. J. Med. Econ. 24, 25\u201333 (2021).","journal-title":"J. Med. Econ."},{"key":"102_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12962-024-00512-9","volume":"22","author":"S Petrou","year":"2024","unstructured":"Petrou, S. & Jakovljevic, M. Reimagining the relationship between economics and health- WHO \u201cHealth for all\u201d provisions. Cost. Eff. Resour. Alloc. 22, 5 (2024).","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"102_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/hcs2.22","volume":"1","author":"SL Chan","year":"2022","unstructured":"Chan, S. L., Lum, E., Ong, M. E. H. & Graves, N. Implementation science: a critical but undervalued part of the healthcare innovation ecosystem. Health Care Sci. 1, 160\u2013165 (2022).","journal-title":"Health Care Sci."},{"key":"102_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","volume":"104","author":"ZS Morris","year":"2011","unstructured":"Morris, Z. S., Wooding, S. & Grant, J. The answer is 17 years, what is the question: understanding time lags in translational research. J. R. Soc. Med. 104, 510\u2013520 (2011).","journal-title":"J. R. Soc. Med."},{"key":"102_CR14","unstructured":"National Institutes of Health. Budget | National Institutes of Health (NIH). https:\/\/www.nih.gov\/about-nih\/what-we-do\/budget (2025)."},{"key":"102_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-014-0657-3","volume":"15","author":"SR Jacobs","year":"2015","unstructured":"Jacobs, S. R. et al. Determining the predictors of innovation implementation in healthcare: a quantitative analysis of implementation effectiveness. BMC Health Serv. Res. 15, 6 (2015).","journal-title":"BMC Health Serv. Res."},{"key":"102_CR16","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it?. Acta Pharm. Sin. B 12, 3049\u20133062 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"102_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s41231-019-0050-7","volume":"4","author":"AA Seyhan","year":"2019","unstructured":"Seyhan, A. A. Lost in translation: the valley of death across preclinical and clinical divide\u2014identification of problems and overcoming obstacles. Transl. Med. Commun. 4, 18 (2019).","journal-title":"Transl. Med. Commun."},{"key":"102_CR18","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1017\/S026646232200335X","volume":"39","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Using early health economic modeling to inform medical innovation development: a soft robotic sock in poststroke patients in Singapore. Int. J. Technol. Assess. Health Care 39, e4 (2023).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"102_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1017\/S0266462314000026","volume":"30","author":"K Markiewicz","year":"2014","unstructured":"Markiewicz, K., van Til, J. A. & IJzerman, M. J. Medical devices early assessment methods: systematic literature review. Int. J. Technol. Assess. Health Care 30, 137\u2013146 (2014).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"102_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40273-017-0509-1","volume":"35","author":"MJ IJzerman","year":"2017","unstructured":"IJzerman, M. J., Koffijberg, H., Fenwick, E. & Krahn, M. Emerging use of early health technology assessment in medical product development: a scoping review of the literature. Pharmacoeconomics 35, 727\u2013740 (2017).","journal-title":"Pharmacoeconomics"},{"key":"102_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1017\/S0266462313000378","volume":"29","author":"C Henshall","year":"2013","unstructured":"Henshall, C., Schuller, T. & HTAi Policy Forum. Health technology assessment, value-based decision making, and innovation. Int. J. Technol. Assess. Health Care 29, 353\u2013359 (2013).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"102_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S0266462320000215","volume":"36","author":"B O\u2019Rourke","year":"2020","unstructured":"O\u2019Rourke, B., Oortwijn, W., Schuller, T. & International Joint Task Group. The new definition of health technology assessment: a milestone in international collaboration. Int. J. Technol. Assess. Health Care 36, 187\u2013190 (2020).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"102_CR23","unstructured":"Gagliardi, D. Translating Research into Innovation: Lessons from 3 Case Studies in Health Partnerships. https:\/\/www.era-learn.eu\/news-events\/news\/translating-research-into-innovation-lessons-from-3-case-studies-in-health-partnerships (2023)."},{"key":"102_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.drudis.2021.09.014","volume":"27","author":"T Wang","year":"2022","unstructured":"Wang, T., McAuslane, N., Gardarsdottir, H., Goettsch, W. G. & Leufkens, H. G. M. Building HTA insights into the drug development plan: current approaches to seeking early scientific advice from HTA agencies. Drug Discov. Today 27, 347\u2013353 (2022).","journal-title":"Drug Discov. Today"},{"key":"102_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1017\/S026646230909059X","volume":"25","author":"L Sampietro-Colom","year":"2009","unstructured":"Sampietro-Colom, L., Asua, J., Briones, E., Gol, J. & AuNETS Group. History of health technology assessment: Spain. Int. J. Technol. Assess. Health Care 25, 163\u2013173 (2009).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"102_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","volume":"22","author":"M Sittimart","year":"2024","unstructured":"Sittimart, M. et al. An overview of the perspectives used in health economic evaluations. Cost. Eff. Resour. Alloc. 22, 41 (2024).","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"102_CR27","doi-asserted-by":"publisher","first-page":"1315294","DOI":"10.1080\/20016689.2017.1315294","volume":"5","author":"P Calcoen","year":"2017","unstructured":"Calcoen, P., Boer, A. & van de Ven, W. P. M. M. Should new health technology be available only for patients able and willing to pay?. J. Mark. Access Health Policy 5, 1315294 (2017).","journal-title":"J. Mark. Access Health Policy"},{"key":"102_CR28","doi-asserted-by":"publisher","first-page":"121000","DOI":"10.1016\/j.techfore.2021.121000","volume":"172","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Rattanavipapong, W. & Teerawattananon, Y. Using health technology assessment to set priority, inform target product profiles, and design clinical study for health innovation. Technol. Forecast. Soc. Change 172, 121000 (2021).","journal-title":"Technol. Forecast. Soc. Change"},{"key":"102_CR29","doi-asserted-by":"publisher","first-page":"948161","DOI":"10.3389\/fphar.2022.948161","volume":"13","author":"T Wang","year":"2022","unstructured":"Wang, T., McAuslane, N., Goettsch, W. G., Leufkens, H. G. M. & De Bruin, M. L. Challenges and opportunities for companies to build hta\/payer perspectives into drug development through the use of a dynamic target product profile. Front. Pharmacol. 13, 948161 (2022).","journal-title":"Front. Pharmacol."},{"key":"102_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2165\/00019053-199711050-00002","volume":"11","author":"H Grabowski","year":"1997","unstructured":"Grabowski, H. The effect of pharmacoeconomics on company research and development decisions. Pharmacoeconomics 11, 389\u2013397 (1997).","journal-title":"Pharmacoeconomics"},{"key":"102_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2165\/00019053-199609030-00007","volume":"9","author":"J Mauskopf","year":"1996","unstructured":"Mauskopf, J., Schulman, K., Bell, L. & Glick, H. A strategy for collecting pharmacoeconomic data during phase II\/III clinical trials. Pharmacoeconomics 9, 264\u2013277 (1996).","journal-title":"Pharmacoeconomics"},{"key":"102_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3109\/10601339809109196","volume":"15","author":"CR Terr\u00e9s","year":"1998","unstructured":"Terr\u00e9s, C. R. Pharmacoeconomic analysis in new drug development: a pragmatic approach to efficiency studies. Clin. Res. Regul. Aff. 15, 209\u2013223 (1998).","journal-title":"Clin. Res. Regul. Aff."},{"key":"102_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1017\/S0266462306051014","volume":"22","author":"H Dong","year":"2006","unstructured":"Dong, H. & Buxton, M. Early assessment of the likely cost-effectiveness of a new technology: a Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement. Int. J. Technol. Assess. Health Care 22, 191\u2013202 (2006).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"102_CR34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.parkreldis.2006.04.006","volume":"12","author":"J Hjelmgren","year":"2006","unstructured":"Hjelmgren, J. et al. Estimating the value of novel interventions for Parkinson\u2019s disease: an early decision-making model with application to dopamine cell replacement. Parkinsonism Relat. Disord. 12, 443\u2013452 (2006).","journal-title":"Parkinsonism Relat. Disord."},{"key":"102_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1017\/S0266462307080051","volume":"24","author":"JB Pietzsch","year":"2008","unstructured":"Pietzsch, J. B. & Pat\u00e9-Cornell, M. E. Early technology assessment of new medical devices. Int. J. Technol. Assess. Health Care 24, 36\u201344 (2008).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"102_CR36","first-page":"Doc11","volume":"20","author":"A Conrads-Frank","year":"2022","unstructured":"Conrads-Frank, A. et al. Decision-analytic modeling for early health technology assessment of medical devices\u2014a scoping review. Ger. Med. Sci. 20, Doc11 (2022).","journal-title":"Ger. Med. Sci."},{"key":"102_CR37","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.techfore.2016.07.041","volume":"112","author":"K Markiewicz","year":"2016","unstructured":"Markiewicz, K., van Til, J. A., Steuten, L. M. G. & IJzerman, M. J. Commercial viability of medical devices using Headroom and return on investment calculation. Technol. Forecast. Soc. Change 112, 338\u2013346 (2016).","journal-title":"Technol. Forecast. Soc. Change"},{"key":"102_CR38","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.jval.2021.12.003","volume":"25","author":"JPC Grutters","year":"2022","unstructured":"Grutters, J. P. C., Kluytmans, A., van der Wilt, G. J. & Tummers, M. Methods for early assessment of the societal value of health technologies: a scoping review and proposal for classification. Value Health 25, 1227\u20131234 (2022).","journal-title":"Value Health"},{"key":"102_CR39","unstructured":"National Institute for Health and Care Excellence. National Institute for Health and Care Excellence. National Institute for Health and Care Excellence https:\/\/www.nice.org.uk\/."},{"key":"102_CR40","unstructured":"Hyseni, L., Latimer, L., Islam, E. & Wilson, H. Overview | Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment | Guidance|NICE. https:\/\/www.nice.org.uk\/guidance\/htg660 (2023)."},{"key":"102_CR41","unstructured":"ASSESS Platform. https:\/\/assessplatform.com\/#:~:text=The%20ASSESS%20Platform%20connects%20those,bring%20the%20product%20to%20market."},{"key":"102_CR42","doi-asserted-by":"publisher","first-page":"A264","DOI":"10.1016\/j.jval.2013.03.1357","volume":"16","author":"L Levin","year":"2013","unstructured":"Levin, L. et al. Excite\u2014a new collaborative model of pre-market evaluation of health technologies. Value Health 16, A264 (2013).","journal-title":"Value Health"},{"key":"102_CR43","unstructured":"New Partnership to Establish Ontario as Premier Site in Pre-Market Evaluation of Medical Technologies - MaRS Discovery District. https:\/\/www.marsdd.com\/media-centre\/new-partnership-to-establish-ontario-as-premier-site-in-pre-market-evaluation-of-medical-technologies\/."},{"key":"102_CR44","unstructured":"Medical Innovation Development and Assessment Support. https:\/\/www.midas-health.com\/."},{"key":"102_CR45","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1017\/S0266462325100123","volume":"41","author":"JPC Grutters","year":"2025","unstructured":"Grutters, J. P. C. et al. Defining early health technology assessment: building consensus using Delphi technique. Int. J. Technol. Assess. Health Care 41, e34 (2025).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"102_CR46","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2165\/11593380-000000000-00000","volume":"9","author":"MJ Ijzerman","year":"2011","unstructured":"Ijzerman, M. J. & Steuten, L. M. G. Early assessment of medical technologies to inform product development and market access: a review of methods and applications. Appl. Health Econ. Health Policy 9, 331\u2013347 (2011).","journal-title":"Appl. Health Econ. Health Policy"},{"key":"102_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-019-4305-9","volume":"19","author":"V Smith","year":"2019","unstructured":"Smith, V. et al. Defining the clinician\u2019s role in early health technology assessment during medical device innovation - a systematic review. BMC Health Serv. Res 19, 514 (2019).","journal-title":"BMC Health Serv. Res"},{"key":"102_CR48","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.healthpol.2017.06.006","volume":"121","author":"I Fasterholdt","year":"2017","unstructured":"Fasterholdt, I., Krahn, M., Kidholm, K., Yderstr\u00e6de, K. B. & Pedersen, K. M. Review of early assessment models of innovative medical technologies. Health Policy 121, 870\u2013879 (2017).","journal-title":"Health Policy"},{"key":"102_CR49","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1017\/S0266462325100299","volume":"41","author":"J Fibla-Reixachs","year":"2025","unstructured":"Fibla-Reixachs, J. What can early HTA bring to needs-based innovation?. Int. J. Technol. Assess. Health Care 41, e46 (2025).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"102_CR50","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1017\/S0266462325100482","volume":"41","author":"D Jarrom","year":"2025","unstructured":"Jarrom, D. Early health technology assessment: current and future perspectives from a health technology assessment agency. Int. J. Technol. Assess. Health Care 41, e68 (2025).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"102_CR51","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1017\/S0266462314000713","volume":"30","author":"M Cuche","year":"2014","unstructured":"Cuche, M., Beckerman, R., Chowdhury, C. A. & van Weelden, M. A. Early dialogue with health technology assessment bodies: a European perspective. Int. J. Technol. Assess. Health Care 30, 571\u2013578 (2014).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"102_CR52","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jval.2023.05.001","volume":"26","author":"W Chen","year":"2023","unstructured":"Chen, W. et al. Evaluating the value for money of precision medicine from early cycle to market access: a comprehensive review of approaches and challenges. Value Health 26, 1425\u20131434 (2023).","journal-title":"Value Health"},{"key":"102_CR53","doi-asserted-by":"publisher","first-page":"A695","DOI":"10.1016\/j.jval.2017.08.1784","volume":"20","author":"O Palkmets","year":"2017","unstructured":"Palkmets, O., Nagda, N. & Sear, R. Early HTA advice in European countries: scope and associated costs. Value Health 20, A695 (2017).","journal-title":"Value Health"},{"key":"102_CR54","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/bmj.p311","volume":"380","author":"J Wise","year":"2023","unstructured":"Wise, J. NICE recommends digital CBT for children and young people. BMJ 380, 311 (2023).","journal-title":"BMJ"},{"key":"#cr-split#-102_CR55.1","unstructured":"Bansback, N. et al. What Are the Characteristics of a Cost-Effective Psoriatic Arthritis Biomarker Test? An Early Health Technology Assessment [abstract]. Arthritis Rheumatol. 2023"},{"key":"#cr-split#-102_CR55.2","unstructured":"75 (suppl 9) https:\/\/acrabstracts.org\/abstract\/what-are-the-characteristics-of-a-cost-effective-psoriatic-arthritis-biomarker-test-an-early-health-technology-assessment\/ (2023)."},{"key":"102_CR56","unstructured":"HITAP|EE TRAINING \u2013 Health Economic and Evaluation Training. https:\/\/eetraining.hitap.net\/."},{"key":"102_CR57","unstructured":"MIDAS MedInno Hackathon 2025 | Innovate and Elevate. https:\/\/medinnohackathon.midas-health.com\/."},{"key":"102_CR58","doi-asserted-by":"publisher","DOI":"10.34172\/ijhpm.8756","author":"W Chen","year":"2025","unstructured":"Chen, W. et al. Development of the PICCOTEAM reference case for economic evaluation of precision medicine. Int. J. Health Policy Manag https:\/\/doi.org\/10.34172\/ijhpm.8756 (2025).","journal-title":"Int. J. Health Policy Manag"},{"key":"102_CR59","unstructured":"Cost-Effectiveness of Cascade Testing for Familial Hypercholesterolemia in Thailand: A Comparative Analysis of Genome Sequencing Methods Across Development Stages - HITAP. https:\/\/www.hitap.net\/en\/document\/policy-brief-182-cascade-testing-familial-hypercholesterolemia-thailand\/."},{"key":"102_CR60","unstructured":"Early HTA: A Guide for Developing Pulmonary Tuberculosis Cost-Effective Tests Fitting the Healthcare Needs - HITAP. https:\/\/www.hitap.net\/en\/document\/policy-brief-189-early-hta-tb-cost-effective-tests\/."},{"key":"102_CR61","doi-asserted-by":"publisher","first-page":"100533","DOI":"10.1016\/j.lansea.2025.100533","volume":"33","author":"L Mou","year":"2025","unstructured":"Mou, L. et al. Early health technology assessment of tongue swab for non-sputum based pulmonary tuberculosis diagnosis in Thailand. Lancet Reg. Health Southeast Asia 33, 100533 (2025).","journal-title":"Lancet Reg. Health Southeast Asia"},{"key":"102_CR62","unstructured":"PRISM Tool | Prism Midas Health. https:\/\/prism.midas-health.com\/prism-tool\/."},{"key":"102_CR63","doi-asserted-by":"publisher","unstructured":"Stone, M. The product life cycle. in Product Planning 45\u201362 https:\/\/doi.org\/10.1007\/978-1-349-02250-2_4 (Palgrave Macmillan UK, 1976).","DOI":"10.1007\/978-1-349-02250-2_4"},{"key":"102_CR64","doi-asserted-by":"publisher","unstructured":"Kenneth Udokporo, C. Understanding the stages of the product life cycle. in Product Life Cycle - Opportunities for Digital and Sustainable Transformation (eds. Petrillo, A. & De Felice, F.) https:\/\/doi.org\/10.5772\/intechopen.99036 (IntechOpen, 2021).","DOI":"10.5772\/intechopen.99036"},{"key":"102_CR65","first-page":"25","volume":"29","author":"G Salazar","year":"2021","unstructured":"Salazar, G. & Russi-Vigoya, M. N. Technology readiness level as the foundation of human readiness level. Ergonom. Des. Q. Hum. Factors Appl. 29, 25\u201329 (2021).","journal-title":"Ergonom. Des. Q. Hum. Factors Appl."},{"key":"102_CR66","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/jama.2009.1987","volume":"303","author":"ER Dorsey","year":"2010","unstructured":"Dorsey, E. R. et al. Funding of US biomedical research, 2003\u20132008. JAMA 303, 137\u2013143 (2010).","journal-title":"JAMA"},{"key":"102_CR67","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1740-9713.2006.00200.x","volume":"3","author":"I Chalmers","year":"2006","unstructured":"Chalmers, I. Biomedical research: are we getting value for money?. Significance 3, 172\u2013175 (2006).","journal-title":"Significance"},{"key":"102_CR68","first-page":"5595","volume":"2009","author":"MB Privitera","year":"2009","unstructured":"Privitera, M. B., Design, M. & Johnson, J. Interconnections of basic science research and product development in medical device design. Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. 2009, 5595\u20135598 (2009).","journal-title":"Annu. Int. Conf. IEEE Eng. Med. Biol. Soc."},{"key":"102_CR69","doi-asserted-by":"crossref","unstructured":"Karia, D., Nambiar, R. S., Maurya, A. P., Ramesh, A. & Arora, M. Application of Waterfall Design Process in Designing of a Holistic System for Children with Hearing Impairment in Resource-Constrained Settings. in Research into Design for a Connected World: Proceedings of ICoRD 2019 Volume 1 (ed. Chakrabarti, A.) vol. 134 929\u2013940 (Springer Singapore, 2019).","DOI":"10.1007\/978-981-13-5974-3_80"},{"key":"102_CR70","doi-asserted-by":"publisher","first-page":"1204853","DOI":"10.3389\/fped.2023.1204853","volume":"11","author":"N Kapol","year":"2023","unstructured":"Kapol, N. et al. Using an experiment among clinical experts to determine the cost and clinical impact of rapid whole exome sequencing in acute pediatric settings. Front. Pediatr. 11, 1204853 (2023).","journal-title":"Front. Pediatr."},{"key":"102_CR71","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/ACM.0b013e3181ccd618","volume":"85","author":"DM Rubio","year":"2010","unstructured":"Rubio, D. M. et al. Defining translational research: implications for training. Acad. Med. 85, 470\u2013475 (2010).","journal-title":"Acad. Med."},{"key":"102_CR72","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/jpm11030216","volume":"11","author":"R De Maria Marchiano","year":"2021","unstructured":"De Maria Marchiano, R. et al. Translational research in the era of precision medicine: where we are and where we will go. J. Pers. Med. 11, 216 (2021).","journal-title":"J. Pers. Med."},{"key":"102_CR73","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semradonc.2011.09.008","volume":"22","author":"A Zietman","year":"2012","unstructured":"Zietman, A. & Ibbott, G. A clinical approach to technology assessment: how do we and how should we choose the right treatment?. Semin. Radiat. Oncol. 22, 11\u201317 (2012).","journal-title":"Semin. Radiat. Oncol."},{"key":"102_CR74","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1017\/S0266462319000667","volume":"35","author":"Y Teerawattananon","year":"2019","unstructured":"Teerawattananon, Y. et al. Landscape analysis of health technology assessment (HTA): systems and practices in Asia. Int. J. Technol. Assess. Health Care 35, 416\u2013421 (2019).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"102_CR75","doi-asserted-by":"publisher","first-page":"2244561","DOI":"10.1080\/23779497.2023.2244561","volume":"8","author":"R Soong","year":"2023","unstructured":"Soong, R., Bradford, E., Yeh, K. B. & Olinger, G. Jr. Using a Target Product Profile (TPP) to guide innovation for future In Vitro Diagnostic (IVD) developments in the United States. Global Secur. Health Sci. Policy 8, 2244561 (2023).","journal-title":"Global Secur. Health Sci. Policy"},{"key":"102_CR76","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1748-720X.2012.00661.x","volume":"40","author":"A Grover","year":"2012","unstructured":"Grover, A., Citro, B., Mankad, M. & Lander, F. Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health. J. Law Med. Ethics 40, 234\u2013250 (2012).","journal-title":"J. Law Med. Ethics"},{"key":"102_CR77","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.healthpol.2008.05.011","volume":"89","author":"S Hartz","year":"2009","unstructured":"Hartz, S. & John, J. Public health policy decisions on medical innovations: what role can early economic evaluation play?. Health Policy 89, 184\u2013192 (2009).","journal-title":"Health Policy"},{"key":"102_CR78","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/bju.13861","volume":"120","author":"S Dijkstra","year":"2017","unstructured":"Dijkstra, S. et al. Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model. BJU Int. 120, 659\u2013665 (2017).","journal-title":"BJU Int."},{"key":"102_CR79","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1177\/0272989X19866415","volume":"39","author":"L Abel","year":"2019","unstructured":"Abel, L. et al. Early economic evaluation of diagnostic technologies: experiences of the NIHR diagnostic evidence co-operatives. Med. Decis. Mak. 39, 857\u2013866 (2019).","journal-title":"Med. Decis. Mak."},{"key":"102_CR80","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10198-021-01276-2","volume":"23","author":"E Gon\u00e7alves","year":"2022","unstructured":"Gon\u00e7alves, E. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions. Eur. J. Health Econ. 23, 155\u2013163 (2022).","journal-title":"Eur. J. Health Econ."},{"key":"102_CR81","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1017\/S0266462323000144","volume":"39","author":"T Wang","year":"2023","unstructured":"Wang, T., McAuslane, N., Goettsch, W. G., Leufkens, H. G. M. & De Bruin, M. L. Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement. Int. J. Technol. Assess. Health Care 39, e20 (2023).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"102_CR82","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jval.2017.11.003","volume":"21","author":"T Wang","year":"2018","unstructured":"Wang, T., McAuslane, N., Liberti, L., Leufkens, H. & H\u00f6vels, A. Building synergy between regulatory and HTA agencies beyond processes and procedures: can we effectively align the evidentiary requirements? A survey of stakeholder perceptions. Value Health 21, 707\u2013714 (2018).","journal-title":"Value Health"},{"key":"102_CR83","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1586\/14737167.2013.814962","volume":"13","author":"B Tsoi","year":"2013","unstructured":"Tsoi, B. et al. Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences. Expert Rev. Pharmacoecon. Outcomes Res. 13, 497\u2013511 (2013).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"102_CR84","doi-asserted-by":"publisher","first-page":"1151504","DOI":"10.3389\/fpubh.2023.1151504","volume":"11","author":"W Chen","year":"2023","unstructured":"Chen, W. et al. Mapping the value for money of precision medicine: a systematic literature review and meta-analysis. Front. Public Health 11, 1151504 (2023).","journal-title":"Front. Public Health"},{"key":"102_CR85","doi-asserted-by":"publisher","first-page":"575","DOI":"10.15171\/ijhpm.2019.36","volume":"8","author":"JPC Grutters","year":"2019","unstructured":"Grutters, J. P. C. et al. Problems and promises of health technologies: the role of early health economic modeling. Int. J. Health Policy Manag. 8, 575\u2013582 (2019).","journal-title":"Int. J. Health Policy Manag."},{"key":"102_CR86","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1524-4733.2010.00726.x","volume":"13","author":"A Girling","year":"2010","unstructured":"Girling, A., Young, T., Brown, C. & Lilford, R. Early-stage valuation of medical devices: the role of developmental uncertainty. Value Health 13, 585\u2013591 (2010).","journal-title":"Value Health"},{"key":"102_CR87","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jval.2022.08.012","volume":"26","author":"M Scholte","year":"2023","unstructured":"Scholte, M. et al. Dealing with uncertainty in early health technology assessment: an exploration of methods for decision making under deep uncertainty. Value Health 26, 694\u2013703 (2023).","journal-title":"Value Health"},{"key":"102_CR88","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/bmj.325.7355.98","volume":"325","author":"DJ Torgerson","year":"2002","unstructured":"Torgerson, D. J. & Byford, S. Economic modelling before clinical trials. BMJ 325, 98 (2002).","journal-title":"BMJ"},{"key":"102_CR89","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1017\/S1744133118000051","volume":"14","author":"M Csan\u00e1di","year":"2019","unstructured":"Csan\u00e1di, M. et al. When health technology assessment is confidential and experts have no power: the case of Hungary. Health Econ. Policy Law 14, 162\u2013181 (2019).","journal-title":"Health Econ. Policy Law"},{"key":"102_CR90","unstructured":"\u00a9Institute for Clinical and Economic Review, 2020 1ICER\u2019s Reference Case for Economic Evaluations: Principles and Rationale. (2020)."},{"key":"102_CR91","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jval.2016.04.015","volume":"19","author":"T Wilkinson","year":"2016","unstructured":"Wilkinson, T. et al. The international decision support initiative reference case for economic evaluation: an aid to thought. Value Health 19, 921\u2013928 (2016).","journal-title":"Value Health"},{"key":"102_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02204-0","volume":"20","author":"D Husereau","year":"2022","unstructured":"Husereau, D. et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 20, 23 (2022).","journal-title":"BMC Med."},{"key":"102_CR93","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.jval.2023.03.009","volume":"26","author":"E Rodriguez Llorian","year":"2023","unstructured":"Rodriguez Llorian, E. et al. Frameworks for health technology assessment at an early stage of product development: a review and roadmap to guide applications. Value Health 26, 1258\u20131269 (2023).","journal-title":"Value Health"},{"key":"102_CR94","unstructured":"Agency for Care Effectiveness. Horizon Scanning methods and process guide. https:\/\/isomer-user-content.by.gov.sg\/68\/795b9d10-8d4a-44f4-9412-c7016f3ffad8\/ace-horizon-scanning-methods-and-process-guide-(mar-2024).pdf (2021)."}],"container-title":["npj Health Systems"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44401-026-00102-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44401-026-00102-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44401-026-00102-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:02:26Z","timestamp":1781856146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44401-026-00102-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["102"],"URL":"https:\/\/doi.org\/10.1038\/s44401-026-00102-2","relation":{},"ISSN":["3005-1959"],"issn-type":[{"value":"3005-1959","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}